Entergy Corp. (ETR) Pops 3.9% for February 18

Equities Staff |

One of the S&P 500’s big winners for Thursday February 18 was Entergy Corp. (ETR) as the company’s stock climbed 3.9% to $73.78 on volume of 1.78 million shares.

The stock opened at $71.55 and saw an intraday low of $70.80 and an intraday high of $73.93. All told, the day saw a per-share gain of $2.77. The stock’s average daily volume of 1.38 million and 178.39 million shares outstanding. Entergy Corp. now has a 50-day SMA is $67.98 and 200-day SMA is $67.40, and it has a 52-week high of $81.07 and a 52-week low of $61.27.

Entergy Corp is an energy company. It is engaged in electric power production and retail electric distribution operations.

Based out of New Orleans, LA, Entergy Corp. has 13,000 employees and, after today’s trading, reached a market cap of $13.16 billion. Its P/S ratio is n/a, P/B ratio is 1.44, and P/FCF ratio is 8.2.

For a complete fundamental analysis analysis of Entergy Corp., check out Equities.com’s Stock Valuation Analysis report for ETR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…